Clinical Trial Update: A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating giredestrant for ER+/HER2- early breast cancer in participants intolerant to adjuvant aromatase inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Giredestrant (giredestrant)

Snippet

Sponsor: Genentech, Inc. | Conditions: Early Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING